FDA grants orphan status to two Lux products

Article

The FDA has granted orphan drug designation to two of Lux Bioscience's investigational therapies.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
Related Content
Two elderly people look at a map. Image credit: ©Rawpixel.com – stock.adobe.com

Study examines navigation performance in glaucoma with virtual-reality-based assessment of path integration

David Hutton
September 16th 2024
Article

Uncertainty during everyday navigation tasks may adversely affect quality of life for patients with glaucoma

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An audience watches a business person make a presentation at a conference. Image credit: ©kasto – stock.adobe.com

Industry preview: Ophthalmic companies bring updates, new research findings to EURETINA

Hattie Hayes
September 11th 2024
Article

Businesses in the retina care space tease new technologies and cutting-edge therapeutics

The Earth with the EURETINA logo superimposed on top. Image credit: ©dimazel – stock.adobe.com and EURETINA

Celebrate World Retina Day at the 2024 EURETINA Congress

Hattie Hayes
September 10th 2024
Article

As part of the Barcelona meeting, retina specialists can recognise the awareness day early

Placa Reial in Barcelona, Spain. A fountain is lit up by streetlamps. Tourists gather at night. Image credit: ©JackF – stock.adobe.com

24th EURETINA Congress: The art of retina on stage in Barcelona

Lynda Charters
September 10th 2024
Article

Focus on collaboration, career development and innovation

Ramin Tadayoni speaks at the 2023 EURETINA Congress. Image courtesy EURETINA.

Remembering a legend: EURETINA members speak about the Ramin Tadayoni Award

Hattie Hayes
September 9th 2024
Article

The Ramin Tadayoni Award supports the next generation of retina researchers while paying tribute to a leader in the field

© 2024 MJH Life Sciences

All rights reserved.